NATURAL-KILLER/T-CELL LYMPHOMA (NKTCL) SUSCEPTIBILITY PREDICTION, DIAGNOSIS AND THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 15, 2015
app pub date -
Nov 26, 2012
filing date -
Nov 25, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Calculated Rating
|
US Family Size
|
Non-US Coverage
|
Abstract
Natural-Killer T-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.
First Claim
Other Claims data not available
Family
+
−
| Country | kind | publication No. | Filing Date |
|---|---|---|---|
| JP | A | JP2015505669 | Nov 26, 2012 |
| SG | A | SG10201605729T | Nov 26, 2012 |
| EP | B1 | EP2782562 | Nov 26, 2012 |
| SG | A | SG11201402611W | Nov 26, 2012 |
| WO | A2 | WO2013077814 | Nov 26, 2012 |
| CN | B | CN104220051 | Nov 26, 2012 |
| IN | A | IN2014CN04746 | Jun 24, 2014 |
| US | B2 | US10378062 | Jun 06, 2016 |
International Classification(s)
- 2012 Application Filing Year
- A61K Class
- 11964 Applications Filed
- 9694 Patents Issued To-Date
- 81.03 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 10 Age